After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare disease has an especially ...
Feb 5, 2025
0
22
For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage of patients and a higher incidence of grade 3 or 4 infections than with either therapy alone, according ...
Jan 9, 2025
0
1
Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy where patients' T-cells are collected and genetically modified to produce chimeric antigen receptors that recognize specific targets on cancer ...
Dec 17, 2024
0
0
For patients with haploidentical hematopoietic cell transplantation (haplo-HCT), the addition of itacitinib to standard graft versus host disease (GvHD) prophylaxis is well tolerated and results in low rates of cytokine release ...
Dec 10, 2024
0
0
As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children's Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine discovered a novel cause ...
Dec 2, 2024
0
148
Researchers report results of the first-in-human phase 1 clinical trials of a novel immunotherapy approach for solid tumors expressing glypican-3 (GPC3). A team from Baylor College of Medicine and Texas Children's Cancer ...
Nov 27, 2024
0
2
In the first study to report real-world outcomes from ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR)-T therapy for multiple myeloma, patients experienced efficacy and safety results similar to those ...
Oct 4, 2024
0
15
In the largest prospective study to date examining the use of chimeric antigen receptor (CAR)-T therapy in a community setting on an outpatient basis, patients with relapsed or refractory large B-cell lymphoma (LBCL) responded ...
Sep 30, 2024
0
21
Universitätsmedizin Berlin is astounded by the huge improvement seen in a female patient with severe systemic lupus erythematosus (SLE) after being treated with the cancer medication teclistamab. Not long ago, the 23-year-old ...
Sep 5, 2024
0
68
Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human Phase I trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, ...
Jun 12, 2024
0
1
